(Q24308684)

GOA release 2020-03-11

1 reference

Takashi Takahashi

11

0 references

author name string

Tomoya Yamaguchi

1

0 references

Kiyoshi Yanagisawa

2

0 references

Ryoji Sugiyama

3

0 references

Yasuyuki Hosono

4

0 references

Yukako Shimada

5

0 references

Chinatsu Arima

6

0 references

Seiichi Kato

7

0 references

Shuta Tomida

8

0 references

Motoshi Suzuki

9

0 references

Hirotaka Osada

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy

10

0 references

language of work or name

English

0 references

publication date

20 March 2012

0 references

published in

Cancer Cell

0 references

volume

21

0 references

issue

3

0 references

page(s)

348-61

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

The Ror receptor tyrosine kinase family

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

ErbB receptors: new insights on mechanisms and biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Ror receptor tyrosine kinases: orphans no more

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

1 reference

7 January 2021

The hunting of the Src

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Characterizing the cancer genome in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Lineage dependency and lineage-survival oncogenes in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

1 reference

7 January 2021

Akt activation by growth factors is a multiple-step process: the role of the PH domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Modeling oncogene addiction using RNA interference.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Src kinase activation by direct interaction with the integrin β cytoplasmic domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Regulation of Akt/PKB activation by tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

TTF-1 expression in pulmonary adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

EGFR mutation is specific for terminal respiratory unit type adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Transcriptional control of lung morphogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2012.02.008

7 January 2021